Find a service?

Contact Request

NCT07560111

A Phase II Study of GC101 in NSCLC

Registry fields

Overall status: RECRUITING
Conditions: Non Small Cell Lung Cancer
Study type: INTERVENTIONAL
Phase: PHASE2
Primary purpose: TREATMENT
Intervention type: BIOLOGICAL
Interventions: Autologous Tumor Infiltrating Lymphocytes
Lead sponsor: Shanghai Juncell Therapeutics (INDUSTRY)

Cached at: 2026-08-06 08:36:53

View on ClinicalTrials.gov

Brief summary

28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report